Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.06. | Filament Health Enters Into Exclusive License Agreement With University Of Alabama At Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder | 2 | CNW | ||
11.06. | Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder | 1 | CNW | ||
28.05. | Filament Health Announces Transition From Otcqb To Otc Pink Limited | 3 | CNW | ||
22.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.05.2025 | 613 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.05.2025.ISIN NameCA31685W1068 FILAMENT... ► Artikel lesen | |
22.05. | XFRA 7QS: AUSSETZUNG/SUSPENSION | 199 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILAMENT HEALTH... ► Artikel lesen | |
20.05. | Filament Health Corp: Filament shares to delist from Cboe Canada May 21 | 1 | Stockwatch | ||
19.05. | Filament Health Corp.: Filament Health Announces Voluntary Delisting From Cboe Canada | 117 | PR Newswire | VANCOUVER, BC, May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
FILAMENT HEALTH Aktie jetzt für 0€ handeln | |||||
09.05. | Filament Health reports Q1 results | 1 | Seeking Alpha | ||
09.05. | Filament Health Corp.: Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights | 48 | PR Newswire | VANCOUVER, BC, May 8, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
09.04. | Filament Health Corp: Filament receives U.S. FDA OK for PEX010 study | 1 | Stockwatch | ||
09.04. | Filament Health Announces Fda Authorization Of Phase 2 Clinical Trial Studying Pex010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder | 2 | CNW | ||
04.04. | Filament Health to raise C$0.9M, delist from Cboe Canada | 1 | Seeking Alpha | ||
04.04. | Filament Health Corp: Filament Health arranges $900,000 private placement | 2 | Stockwatch | ||
04.04. | Filament Health Corp.: Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada | 125 | PR Newswire | Financing driven by existing investor Negev and Filament's Board of Directors
Company also announces intention to voluntarily delist from Cboe Canada
VANCOUVER... ► Artikel lesen | |
01.04. | Filament Health Corp.: Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights | 83 | PR Newswire | VANCOUVER, BC, April 1, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
01.04. | Filament Health reports FY results | 1 | Seeking Alpha | ||
17.03. | Filament Health Corp: Filament Health talks PEX010 safety data | 1 | Stockwatch | ||
17.03. | Filament Health Corp.: Filament Health Announces Positive Data From Phase 2 Study Of Pex010 In Patients With Alcohol Use Disorder | 74 | PR Newswire | Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botanical psilocybin... ► Artikel lesen | |
06.02. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference | 452 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as... ► Artikel lesen | |
22.01. | Filament Health Corp: Filament Health ships PEX010 to UW-Madison | 1 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,975 | +2,64 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.06.2025... ► Artikel lesen | |
AURORA CANNABIS | 3,540 | +0,28 % | Aurora Cannabis Inc (3): Aurora Cannabis expands compassionate pricing program | ||
CANOPY GROWTH | 1,036 | -0,19 % | Canopy Growth Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
TILRAY BRANDS | 0,344 | +0,09 % | Tilray Brands, Inc.: Tilray Medical erhält vom italienischen Gesundheitsministerium die erste Genehmigung für den Vertrieb von medizinischen Cannabisblüten für therapeutische Zwecke | SAVONA, Italien, June 25, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und weltweit führender Anbieter von medizinischem... ► Artikel lesen | |
INNOCAN PHARMA | 0,145 | +2,11 % | Breaking News: Innocan Pharma - der Superstar auf der "PAINWEEK"? | ||
CRONOS GROUP | 1,614 | -0,31 % | Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders | TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June... ► Artikel lesen | |
SYNBIOTIC | 3,055 | -1,93 % | SYNBIOTIC SE: Online-Präsentation für Investoren am 01.07.2025 | SYNBIOTIC SE ist ein führendes, börsennotiertes Unternehmen aus Deutschland mit Schwerpunkt auf Hanf, Cannabis und Cannabinoiden. Das Unternehmen verfolgt eine paneuropäische Buy-and-Build-Strategie... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 4,500 | +1,08 % | Green Thumb Industries Reports First Quarter 2025 Results | CHICAGO and VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
CHRISTINA LAKE CANNABIS | 0,018 | +20,00 % | Christina Lake Cannabis Corp.: Christina Lake Cannabis Announces Financing | VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the "Company" or "CLC" or "Christina Lake Cannabis") (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) the Company... ► Artikel lesen | |
AXSOME THERAPEUTICS | 89,44 | +1,25 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia | NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today... ► Artikel lesen | |
JAGUAR HEALTH | 2,500 | -7,75 % | Jaguar Health, Inc.: Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset | Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 92,32 | +1,05 % | Jazz Pharmaceuticals plc: Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer | Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically... ► Artikel lesen | |
TRULIEVE CANNABIS | 3,040 | +0,93 % | Trulieve Cannabis Corp: Trulieve to open dispensary in Florida | ||
CORBUS PHARMACEUTICALS | 6,350 | -7,97 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab | Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and... ► Artikel lesen | |
CANNOVUM CANNABIS | 0,211 | -17,25 % | EQS-News: Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich | EQS-News: Cannovum Cannabis AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Sonstiges
Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich... ► Artikel lesen |